The Risk of Psychiatric Disorders in Finasteride Users with Benign Prostatic Hyperplasia and Androgenetic Alopecia: A Population-Based Case-Control Study

    August 2024 in “ Australasian Journal of Dermatology ”
    Anna Lyakhovitsky, Boaz Amichai, Eran Galili, Arnon D. Cohen, Khalaf Kridin, Zvi Segal, Doron Netzer
    Image of study
    TLDR Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.
    This large-scale population-based case-control study investigated the association between finasteride therapy for benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA) and the emergence of psychiatric disorders. The study included 307 men with BPH and 23,227 men with AGA, along with their respective control groups. Results showed that 2.3% of BPH patients experienced mental health outcomes, with no significant increase compared to controls. However, AGA patients had slightly higher rates of anxiety and depression compared to controls (0.6% vs. 0.4% and 0.5% vs. 0.4%, respectively). Multivariate regression models identified finasteride as a risk factor for anxiety (OR 1.449) and depression (OR 1.439) in AGA patients. Overall, finasteride users had a very low rate of adverse mental health effects, with no increase in psychological sequelae in BPH patients and a slight increase in anxiety and depression in AGA patients.
    Discuss this study in the Community →

    Research cited in this study

    18 / 18 results

    Related Community Posts Join

    6 / 1000+ results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  43 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 8 months ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

      community Dermatologist told me to quit fin after turning 40

      in Finasteride/Dutasteride  194 upvotes 1 year ago
      A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

    Related Research

    6 / 6 results